News | Patient Monitors | June 18, 2019

First-in-Human Results Show Early Bird Device Effective in Early Detection of Internal Bleeding

One in five patients impacted by internal bleeding during endovascular procedures

First-in-Human Results Show Early Bird Device Effective in Early Detection of Internal Bleeding

June 18, 2019 – New study results validate the effectiveness of the Saranas Early Bird Bleed Monitoring System to sense bleeding events during endovascular-related procedures by using sensors to detect relative changes in tissue bioimpedance. The study enrolled 60 patients from five sites who underwent an endovascular procedure and detected bleeding in more than half of patients. The results of this study were presented as late- breaking clinical research on at the Society for Cardiovascular Angiography Interventions (SCAI) 2019 Scientific Sessions, May 19-22 in Las Vegas.

One in five patients experience a bleeding complication during large-bore endovascular procedures such as transcatheter aortic valve replacement (TAVR), endovascular aneurysm repair and percutaneous left ventricular assist device implant. This complication is associated with significant increase in risk of mortality, length of hospital stay and healthcare costs, according to a 2017Journal of the American Medical Association study. The Early Bird is designed to be integrated during endovascular procedures and inserted in a vessel in anticipation of a bleed. The technology was invented at the Texas Heart Institute in Houston.

From August 2018 to December 2018, a total of 60 patients (mean age 76 years, 42 percent females) from five U.S. sites were enrolled and underwent an endovascular procedure (TAVR) 67 percent; percutaneous coronary intervention (PCI) 13 percent; Impella 8 percent; balloon aortic valvuloplasty 7 percent; transcatheter mitral valve replacement (TMVR) 2 percent, endovascular aneurysm repair (EVAR) 2 percent and MitraClip 2 percent). The Early Bird was used during and after endovascular procedures, either as a venous or arterial access sheath. In the case of bleeding, the device has a sensor that detects the onset of bleeding and characterizes bleed progression into I, II and III levels. The primary endpoint was the level of agreement in bleeding detection between the Saranas Early Bird and post-procedural computed tomography (CT).

Early Bird detected bleeding in 63 percent of patients, with 33 percent of those patients at bleeding level I, 23 percent at bleeding level II and seven percent at bleeding level III. No device-related complications were reported.

“This is the first time we’re seeing how this device could help in a real-world patient setting and we were very encouraged by the results. Right now, patients have a risk of vessel injury when undergoing endovascular procedures where the femoral artery or vein is used for vascular access,” said Philippe Genereux, M.D., principal investigator, cardiologist and physician at Morristown Medical Center in Morristown, N.J. “This technology allows us to detect bleeding in real time, which means we can take action quickly and improve the outcomes of the procedure and recovery for the patient.”

Watch the VIDEO: How to Achieve Hemostasis With Large Bore Device Access, an interview with Genereux at TCT 2018

In March, the Early Bird device was granted de novo classification by the U.S. Food and Drug Administration (FDA). Saranas plans to conduct a controlled rollout to institutions interested in having bleed management as part of their standard of care.

The authors note plans to continue research of the device with controlled studies at institutions who have specific interest in bleed management. Post-approval study and practices will evolve as the authors continue to evaluate and collect data on the device.

For more information: www.saranas.com

Read more about late-breaking clinical trials at SCAI

Related Content

News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Subscribe Now